Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
wiki:user:jbaker [2012/10/01 11:46]
jbaker
wiki:user:jbaker [2014/05/13 21:00] (current)
stefan [Publications]
Line 9: Line 9:
 \\ \\
 Funding provided by the Canadian Breast Cancer Foundation\\ Funding provided by the Canadian Breast Cancer Foundation\\
 +{{:​cbcf-bcyukon-logo.jpg?​200|}}
 +</​WRAP>​
  
-My research interests are in the tumour microenvironment,​ blood vessels, blood flow, drug distribution,​ MRI and hypoxia. My current main research focus is investigating the [[wiki:research:trastuzumab|heterogeneous distribution of trastuzumab in breast cancer using MRI and immunohistochemistry.]]+{{:wiki:user:jheb.jpg?​200|}} 
 +\\
  
 + My research interests are in the tumour microenvironment,​ blood vessels, blood flow, drug distribution,​ MRI and hypoxia. My current main research focus is investigating the [[wiki:​research:​trastuzumab|heterogeneous distribution of trastuzumab in breast cancer using MRI and immunohistochemistry.]]
  
- 
-{{:​wiki:​user:​jheb.jpg?​200|}} 
-</​WRAP>​ 
- 
-<WRAP clear></​WRAP>​ 
 We use MRI and immunohistochemistry to examine functional and morphological features of the tumour microenvironment. We have developed custom tools that enable excellent correlation of MR and histology, such that we can use the fine detail of many labeled features within the solid tumour to inform and validate observations made using MRI. Much of this work uses the custom scanning microscope and multiplex immunohistochemistry techniques developed in the [[http://​www.bccrc.ca/​dept/​ic/​radiation-biology-unit/​andrew-minchinton|Minchinton Lab]] at the BC Cancer Research Centre. A sample image of a Her2+ve xenograft is stained for systemically administered,​ unlabeled Herceptin (pink), CD31 vasculature (navy blue), perfusion dye (cyan blue), hypoxia (green), BrdU s-phase cells (black) and hematoxylin (grey). The tumour has a large area of necrosis (white) at the bottom where well-perfused skin is still attached to the tumour. The viable tumour tissue shows microregional heterogeneity:​ some regions have very little bound Herceptin around perfused blood vessels (top, right) whereas other regions have vessels with bound Herceptin several cell layers away from vessels (bottom, left & right). This tumour was collected 24h after a 10 mg/kg ip Herceptin treatment. We use MRI and immunohistochemistry to examine functional and morphological features of the tumour microenvironment. We have developed custom tools that enable excellent correlation of MR and histology, such that we can use the fine detail of many labeled features within the solid tumour to inform and validate observations made using MRI. Much of this work uses the custom scanning microscope and multiplex immunohistochemistry techniques developed in the [[http://​www.bccrc.ca/​dept/​ic/​radiation-biology-unit/​andrew-minchinton|Minchinton Lab]] at the BC Cancer Research Centre. A sample image of a Her2+ve xenograft is stained for systemically administered,​ unlabeled Herceptin (pink), CD31 vasculature (navy blue), perfusion dye (cyan blue), hypoxia (green), BrdU s-phase cells (black) and hematoxylin (grey). The tumour has a large area of necrosis (white) at the bottom where well-perfused skin is still attached to the tumour. The viable tumour tissue shows microregional heterogeneity:​ some regions have very little bound Herceptin around perfused blood vessels (top, right) whereas other regions have vessels with bound Herceptin several cell layers away from vessels (bottom, left & right). This tumour was collected 24h after a 10 mg/kg ip Herceptin treatment.
 <WRAP clear></​WRAP>​ <WRAP clear></​WRAP>​
Line 23: Line 22:
 {{panoview>:​wiki:​user:​jbaker:​herceptin-image.jpg?​500x500|}} {{panoview>:​wiki:​user:​jbaker:​herceptin-image.jpg?​500x500|}}
 </​WRAP>​ </​WRAP>​
- 
-==== Publications ==== 
-<​HTML>​ 
-<script language="​JavaScript"​ type="​text/​javascript">​ 
-        function iFrameHeight(id) { 
-            var e = document.getElementById(id);​ 
-            var h = 0; 
-            if (!document.all) { 
-                h = e.contentDocument.height;​ 
-                e.style.height = h + 600 + '​px';​ 
-            } else if (document.all) { 
-                h = document.frames(id).document.body.scrollHeight;​ 
-                document.all.frames(id).style.height = h + 200 + '​px';​ 
-            } 
-        } 
-</​script>​ 
-<iframe id="​refbase-citations"​ name="​refbase-citations"​ onload="​iFrameHeight('​refbase-citations'​)"​ align="​top"​ width="​100%"​ height="​400px"​ scrolling="​auto"​ frameborder="​0"​ src="​http://​pfeifer.phas.ubc.ca/​refbase/​show.php?​author=Baker&​amp;​Type=Article&​amp;​without=dups&​amp;​submit=Cite&​amp;​citeOrder=year&​amp;​client=inc-refbase-1%2E0&​amp;​showLinks=1&​amp;​showRows=50"​ width="​100%"​ height="​500">​ 
-</p> 
-</​iframe>​ 
-</​HTML>​ 
  
  
Navigation

<ifauth @sarlab> * **[[:intro2wiki|README FIRST]]** </ifauth> * [[:start|Group Home]] * [[:wiki:user:start|Members]] * [[:wiki:user:stefan|Stefan A Reinsberg]] * [[:wiki:user:jbaker|Jennifer Baker]] * [[:wiki:user:jmoroz|Jennifer Moroz]] * [[:wiki:user:fmoosvi|Firas Moosvi]] * [[:wiki:publications|Publications]] * [[:wiki:collaborations|Collaborations]] <ifauth @sarlab> \\ **Protected** * [[:protected:resources|Resources]] * [[:protected:protocols|Protocols ('SOP')]] * [[:protected:experiments|Experiments]] * [[:protected:talks:talks|Talks & Presentations]] </ifauth>

Print/export
QR Code
QR Code Jennifer H. E. Baker (generated for current page)